

This article was downloaded by:

On: 24 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Journal of Liquid Chromatography & Related Technologies

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597273>

### ENANTIOSEPARATION ON AMYLOSE TRIS(3,5-DIMETHOXYPHENYL CARBAMATE): APPLICATION TO COMMERCIAL PHARMACEUTICAL CHIRAL DRUGS

Quezia B. Cass<sup>a</sup>; M. Elizabeth Tiritan<sup>a</sup>; Silvana A. Calafatti<sup>b</sup>; Stephen A. Matlin<sup>c</sup>

<sup>a</sup> Depto. de Química, Universidade Federal de São Carlos, São Carlos, SP, Brasil <sup>b</sup> Universidade São Francisco, SP, Brasil <sup>c</sup> Chemistry Department, Warwick University, Coventry, UK

Online publication date: 17 November 1999

**To cite this Article** Cass, Quezia B. , Tiritan, M. Elizabeth , Calafatti, Silvana A. and Matlin, Stephen A. (1999) 'ENANTIOSEPARATION ON AMYLOSE TRIS(3,5-DIMETHOXYPHENYL CARBAMATE): APPLICATION TO COMMERCIAL PHARMACEUTICAL CHIRAL DRUGS', *Journal of Liquid Chromatography & Related Technologies*, 22: 20, 3091 — 3099

**To link to this Article:** DOI: 10.1081/JLC-100102077

**URL:** <http://dx.doi.org/10.1081/JLC-100102077>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**ENANTIOSEPARATION ON AMYLOSE  
TRIS(3,5-DIMETHOXYPHENYL CARBAMATE):  
APPLICATION TO COMMERCIAL  
PHARMACEUTICAL CHIRAL DRUGS**

Quezia B. Cass,<sup>1,\*</sup> M. Elizabeth Tiritan,<sup>1</sup> Silvana A. Calafatti,<sup>2</sup>  
Stephen A. Matlin<sup>3</sup>

<sup>1</sup>Depto. de Química  
Universidade Federal de São Carlos  
Cx. Postal 676  
São Carlos 13565-905, SP, Brasil

<sup>2</sup>Unidade de Farmacologia  
Universidade São Francisco  
Bragança Paulista 12900-000, SP, Brasil

<sup>3</sup>Chemistry Department  
Warwick University  
Coventry CV4 7AL, UK

**ABSTRACT**

The enantioselectivity of the amylose tris(3,5-dimethoxy-phenyl carbamate) phase towards some  $\beta$ -blockers was investigated. A sensitive HPLC method was developed for the enantiomers of metoprolol and betaxolol. The validated methods were suitable for the analysis of enantiomeric composition in a variety of pharmaceutical formulations of both drugs.

## INTRODUCTION

The growing interest of the pharmaceutical industry in the use of single enantiomers has led to an increasing demand for direct methods for analytical separations of enantiomers of pharmaceuticals.

Among the most useful and versatile chiral analytical columns described in recent years are coated carbohydrate carbamate columns, which were originally developed by Okamoto et al.<sup>1</sup>

The amylose tris(3,5-dimethoxyphenyl carbamate) phase which is readily prepared from commercially available materials, has already showed some advantages over the widely used cellulose and amylose tris(3,5-dimethylphenylcarbamate) phases for the resolution of certain chiral sulphoxides.<sup>2</sup>

The enantioselectivity of this phase towards some  $\beta$ -blockers was investigated in this work.


## EXPERIMENTAL

### General

The columns were prepared as described elsewhere<sup>2</sup> and consisted of amylose tris(3,5-dimethoxyphenyl carbamate) coated onto APS-Nucleosil (7  $\mu$ m particle size and 500 Å pore size) (20% w/w, 15 X 0.45 cm ID), APS-Hypersil (5  $\mu$ m particle size and 120 Å pore size) (20% w/w, 15 X 0.45 cm ID) and ODS-Hypersil (5  $\mu$ m particle size and 120 Å pore size) (15% w/w, 10 X 0.45 cm ID) respectively. The performance of all columns used was first evaluated using Troger's base and *trans*-stilbene oxide. HPLC dead times ( $t_0$ ) were estimated by using 1,3,5-tri-*tert*-butylbenzene. Solvents were either HPLC grade from Merck or from Carlo Erba or were purified as usual.<sup>3</sup>

The standards propranolol and pindolol were donated by Laboratório de Controle de Qualidade, Faculdade de Farmácia UFMG, Belo Horizonte, Brazil. Metoprolol standard was kindly donated by Biogalência Química Farmacêutica, São Paulo, SP, Brazil and betaxolol standard by Alcon Laboratórios do Brasil, São Paulo, SP, Brazil.

The pharmaceutical formulations used were purchased at a drug store as tablets for metoprolol: Lopressor®, Seloken® (Batches N° 25758 and PN011, respectively) and for betaxolol as an ophthalmic solution: Betoptic® (Batch No. RF06) and Betoptic S® as an ophthalmic suspension (Batches 4305 and 4535).

**Figure 1.** Structures of  $\beta$ -Blockers Analyzed.**Table 1**

**Investigation of the Influence of the Silica Surface on the Enantioselectivity  
of the Phase Amylose Tris(3,5-Dimethoxyphenyl Carbamate)**

Supports Used	APS-Nucleosil (500 Å, 7 $\mu$ m)			APS-Hypersil (120 Å, 5 $\mu$ m)			ODS-Hypersil (120, Å, 5 $\mu$ m)		
Drugs	$k'_1$	$\alpha$	$R_s$	$k'_1$	$\alpha$	$R_s$	$k'_1$	$\alpha$	$R_s$
Propranolol	2.10	1.52	1.80	4.10	1.12	0.66	4.6	1.0	---
Pindolol	33.14	1.34	0.60	43.13	1.15	0.74	39.0	1.0	---
Betaxolol	3.22	1.40	1.54	5.65	1.12	0.70	6.0	1.0	---
Metoprolol	3.99	1.46	1.50	7.29	1.13	0.70	8.0	1.0	---

Mobile Phase: Hexane:2-propanol (90:10 v/v).

### Preparation of Samples

#### Standards

The hydrochloride salts of propranolol, pindolol, and betaxolol and the tartarate salt of metoprolol standards (100 mg) were solubilized in a saturated solution of sodium hydrogen carbonate (100 mL) and the free bases were

Table 2

**Influence of the Mobile Phase on the Enantioselectivity of the Phase  
Amylose Tris(3,5-Dimethoxyphenyl carbamate) Coated onto APS-Nucleosil**

Mobile Phase	Betaxolol		Metoprolol	
	$\alpha$	Rs	$\alpha$	Rs
Hexane/2-propanol (90:10 v/v)	1.40	1.54	1.46	1.50
	1.50	1.84	1.31	2.03
Hexane/2-propanol/Et <sub>3</sub> N (90:10:0.1 v/v)	1.42	2.16	1.49	3.10
Hexane/Ethanol (95:05 v/v)	1.45	1.94	1.41	2.30
Hexane/Ethanol (90:10 v/v)	1.37	3.00	1.41	2.76
Hexane/Ethanol (88:12 v/v)	1.45	2.74	1.46	2.63
Hexane/Ethanol (85:15 v/v)	1.40	2.69	1.41	2.45
Hexane/Ethanol/Et <sub>3</sub> N (90:10:0.1 v/v/v)	1.36	2.60	1.40	2.72

extracted with diethyl ether (3x4mL). The organic phase was then washed with water (3x4 mL), dried with sodium sulfate and evaporated *in vacuo* to afford the free bases as a powder, except for the metoprolol which was an oil. They were dissolved in the mobile phase for HPLC analysis.

#### ***Finished Pharmaceuticals***

A pool of three tablets of Seleken® or Lopressor® (100 mg) was macerated and extracted using the same procedure as for the standards. The ophthalmic solution of Betoptic® (1 mL) was diluted in a saturated solution of sodium hydrogen carbonate (10 mL), extracted with diethyl ether (3 x 3 mL), washed with water, dried with sodium sulfate, and evaporated *in vacuo* and the free base dissolved in the mobile phase.

A saturated solution of sodium hydrogen carbonate (10 mL) was added to the ophthalmic suspension of Betoptic S® which was then extracted with diethyl ether (3 x 3 mL), which was washed with brine (3 x 3 mL), water, dried with sodium sulfate, and evaporated *in vacuo*. The residue was then dissolved in the mobile phase for HPLC analysis.

#### **Equipment**

The HPLC system consisted of a Shimadzu LC-10AD pump, a SPD-6AV UV detector operated at 254 nm, and a LC-R6A chromatopac recorder. A Rheodyne 7125 injector fitted with a 20 mL loop was used in both cases. Unless otherwise stated, the flow rate was always 0.5 mL.min.<sup>-1</sup>




Figure 2. Metoprolol calibration curve.

## RESULTS AND DISCUSSION

The enantioselectivity of cellulose tris(3,5-dimethylphenyl carbamate) towards  $\beta$ -adrenergic blockers belonging to the aryloxyamino-2-ol class, which includes propranolol among others, has been extensively evaluated.<sup>4,5</sup> The previous result obtained with the amylose tris (3,5-dimethoxyphenyl carbamate)<sup>2</sup> phase prompted us to further investigate its enantioselectivity and for this purpose the well-studied  $\beta$ -adrenergic blockers drugs propranolol, pindolol, betaxolol, and metoprolol were chosen (Figure 1).

Since it has been shown that different supports can be used efficiently<sup>6</sup> for this class of chiral phase and that the acidity of the support can play an important role in the enantioselectivity of these phases,<sup>7</sup> the influence of the support surface was initially investigated.

When APS-Hypersil was used as support, a marked decreased in resolution was observed when compared with the APS-Nucleosil. However, when ODS-Hypersil was used as the support, no enantioselectivity was observed for the  $\beta$ -blockers examined, although *trans*-stilbene oxide and Troger's base had given a good performance, with capacity ratios  $\alpha$  of 1.96 and 1.32 and resolutions  $R_s$  of 2.10 and 1.53 respectively.

The best enantioselectivity was found when APS-Nucleosil was used as the support and was, therefore, selected for development of the analytical method for pharmaceutical formulations containing metoprolol and betaxolol (Table 1).




Figure 3. Betaxolol calibration curve.

Table 3


**Precision Data for the Determination of the  
Racemic Drugs Betaxolol and Metoprolol**

Drugs	Repeatability*		Reproducibility*	
	1st Enantiomer	2nd Enantiomer	1st Enantiomer	2nd Enantiomer
Betaxolol	1.00	1.43	1.30	2.00
Metoprolol	0.51	1.12	1.46	1.40

\* Expressed as C.V. %

The influence of the mobile phase and addition of a silanol suppressor, such as triethylamine, was investigated. When ethanol was used as the organic modifier, good resolutions were obtained but better peak shape was obtained with ethanol and triethylamine and, for this reason, the later mobile phase was selected.

Capacity ratios  $\alpha$  1.36 for betaxolol and 1.40 for metoprolol and good resolutions  $R_s$  2.60 and 2.72 respectively, were obtained using hexane:ethanol:triethylamine (90:10:0.1v/v) as the mobile phase. (See Table 2.)



**Figure 4.** Chromatograms of (a) betaxolol and (b) metoprolol.

The response of the UV detector at 254 nm was linear from 0.5 to 4.0 mg.mL<sup>-1</sup> for 20 µL injection for the racemic drugs or 0.25 to 2.0 mg. mL<sup>-1</sup> for each enantiomer and the correlation coefficient was superior to 0.999 for both drugs (Figure 2 and 3).

The reproducibility (expressed as CV  $n = 15$ , measured at three different days,  $n = 5$  for each day) and the repeatability ( $n=10$ ) of the method were excellent for both drugs (Table 3).

The quantification limit was determined as the lowest concentration that could be measured with precision of 3% (CV)<sup>8</sup> for five consecutive injections. The values found were 10 µg.mL<sup>-1</sup> for betaxolol and 25 µg. mL<sup>-1</sup> for metoprolol.

Typical chromatograms of metoprolol and betaxolol obtained during the validation study are shown in Figure 4. The validated methods were suitable for the quantitative analysis of enantiomeric composition of a variety of pharmaceutical formulations of both drugs.



**Table 4**

**Enantiomeric Composition of Ophthalmic Solution Betoptic® and Suspension Betoptic S® as Analyzed on the Phase Amylose Tris(3,5-Dimethoxyphenyl Carbamate) Coated onto APS-Nucleosil\***

Finished Pharmaceutical	Batches	Enantiomeric Composition (%)		ee
		1st Enantiomer	2nd Enantiomer	
Betopic®	Rf 06	49.40 ± 0.30	49.53 ± 0.30	---
		50.60 ± 0.30	50.63 ± 0.30	
Betoptic S®	4305	49.75 ± 0.12	50.25 ± 0.12	---
		49.15 ± 0.93	50.84 ± 0.95	
Betoptic S®	4535	50.80 ± 1.11	49.19 ± 1.10	---
		50.93 ± 2.60	49.07 ± 2.70	

\* n = 3, confidence level, 95%; mobile phase: hexane: ethanol: triethylamine (90:10:0.1 v/v/v).

**Table 5**

**Enantiomeric Composition of the Tablets Lopressor® and Seloken® as Analyzed on the Phase Amylose Tris (3,5-Dimethoxyphenyl Carbamate Coated onto APS Nucleosil**

Finished Pharmaceutical	Enantiomeric Composition (%)	
	1st Enantiomer	2nd Enantiomer
Lopressor®*	52.24 ± 0.08	47.76 ± 0.08
	51.90 ± 0.71	58.12 ± 0.80
	52.58 ± 0.60	47.42 ± 0.60
Seloken®**	49.12 ± 0.42	50.81 ± 0.44
	49.30 ± 0.07	50.70 ± 0.07

\* n = 3 confidence level, 95%; \*\* n = 4 confidence level, 95%.

The free base forms of betaxolol and metoprolol were prepared in duplicate from the commercial samples and run in triplicate using the external standard calibration method. The area percent ratio was used to determine the enantiomeric composition. All medicines had the claimed enantiomeric composition (Tables 4 and 5), as expected.

### CONCLUSION

The enantioselectivity of the amylose tris(3,5-dimethoxyphenyl carbamate) phase was demonstrated for the  $\beta$ -blockers analyzed. The method proved to be suitable for the analysis of finished pharmaceuticals.

### ACKNOWLEDGMENTS

We thank FAPESP and CNPq for financial support and CAPES for a grant to S. A. C.

### REFERENCES

1. Y. Okamoto, M. Kawashima, K. Hatada, *J. Am. Chem. Soc.*, **106**, 5357-5359 (1984).
2. S. A. Matlin, M. Elizabeth Tiritan, A. J. Crawford, Q. B. Cass, D. R. Boyd, *Chirality*, **6**, 135-140 (1994).
3. D. Perin, D. Armarego, D. R. Perin, **Purification of Laboratory Chemicals**, 2nd ed., Oxford, Pergamon Press, 1980.
4. Y. Okamoto, M. Kawashima, R. Aburatani, K. Hatada, T. Nihisma, M. Masuda, *Chem. Lett.*, 1237-1240 (1986).
5. A. M Krstulovic, M. H. Fouchet, J. T. Burke, G. Gillet, A. Durand, *Chromatogr.*, **452**, 477-483 (1988).
6. S. J. Grieb, S. A. Matlin, A. M. Belenguer, H. J. Ritchie, *J. Chromatogr. A*, **697**, 271-278 (1995).
7. S. A. Matlin, M. Elizabeth Tiritan, Q. B. Cass, D. R. Boyd, *Chirality*, **8**, 147-152 (1996).
8. D. R. Jenke, *J. Liq. Chrom.& Rel. Techol.*, **19(5)**, 737-757 (1996).

Received March 30, 1999

Accepted April 26, 1999

Manuscript 5044

## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081JLC100102077>